All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, March 30, 2023
Home » Topics » Deals and M&A

Deals and M&A
Deals and M&A RSS Feed RSS

Biocytogen out-licenses bispecific antibody to Chipscreen in ¥596M deal

Feb. 28, 2023
By Doris Yu
No Comments
Biocytogen Pharmaceuticals Co. Ltd.’s wholly owned subsidiary, Eucure Biopharma Co. Ltd., licensed exclusive greater China rights to YH-008 to Chipscreen Biosciences Co. Ltd. in a ¥596 million (US$86 million) deal. Chipscreen subsidiary, Chipscreen Newway Biosciences Co. Ltd., will develop and commercialize the bispecific antibody in mainland China, Hong Kong, Macau and Taiwan.
Read More

Celltrion and Liscure to co-develop microbiome-based Parkinson’s treatment

Feb. 28, 2023
By Tamra Sami
No Comments
South Korean biotech peers Celltrion Healthcare Co. Ltd. and Liscure Biosciences Co. Ltd. signed a deal to co-develop microbiome-based oral live biotherapeutic products for Parkinson's disease.
Read More
Antibody-drug conjugate illustration

Astrazeneca gets global rights to Claudin 18.2 ADC from Lepu, Keymed in $1.2B deal

Feb. 28, 2023
By Doris Yu
No Comments
Indicating its continuing strategy to invest in antibody-drug conjugates (ADCs), Astrazeneca plc obtained exclusive global rights to Claudin 18.2 ADC CMG-901 from Keymed Biosciences Inc. and Lepu Biopharma Co. Ltd. in a deal worth up to $1.163 billion.
Read More
Asia at night from space

Olympus in $370M buy of Taewoong to expand in gastrointestinal endotherapy field

Feb. 27, 2023
By Doris Yu
No Comments
Olympus Corp. has acquired Taewoong Medical Co. Ltd. in a $370 million deal to expand its gastrointestinal (GI) endotherapy product portfolio.
Read More
Stock merger illustration

Struggling Jounce inks all-share merger deal with Redx

Feb. 23, 2023
By Nuala Moran
No Comments
Antibody specialist Jounce Therapeutics Inc. and Redx Pharma plc are to merge in an all-share transaction with a value of $425 million, in a deal that will see Redx’s small-molecule cancer and fibrosis drugs absorbing the lion’s share of the combined cash and its shareholders owning 63% of the combined company.
Read More

To Infinity and beyond? Buzz about Mei’s future could change with all-stock merger

Feb. 23, 2023
By Randy Osborne
No Comments
Aiming to start afresh under a new name, troubled Mei Pharma Inc. wants to merge with Infinity Pharmaceuticals Inc. in an all-stock transaction that would provide the combined outfit enough cash to fund operations through mid-2025. Specifically, coffers of the newly made firm would contain about $100 million for the advancement of three oncology candidates in a pipeline led by Infinity’s phase II-stage eganelisib for head and neck squamous cell carcinoma.
Read More
Antibody-drug conjugate illustration

Astrazeneca gets global rights to Claudin 18.2 ADC from Lepu, Keymed in $1.2B deal

Feb. 23, 2023
By Doris Yu
No Comments
Indicating its continuing strategy to invest in antibody-drug conjugates (ADCs), Astrazeneca plc obtained exclusive global rights to Claudin 18.2 ADC CMG-901 from Keymed Biosciences Inc. and Lepu Biopharma Co. Ltd. in a deal worth up to $1.163 billion.
Read More

Celltrion and Liscure to co-develop microbiome-based Parkinson’s treatment

Feb. 22, 2023
By Tamra Sami
No Comments
South Korean biotech peers Celltrion Healthcare Co. Ltd. and Liscure Biosciences Co. Ltd. signed a deal to co-develop microbiome-based oral live biotherapeutic products for Parkinson's disease. Under the agreement, Celltrion, of Incheon, South Korea, will provide Seoul-based Liscure with research funding as well as additional payments as the project progresses. Liscure will lead discovery of the novel candidates, and Celltrion will be responsible for further clinical and regulatory development.
Read More
M&A cityscape

US FTC sites record-breaking number of mergers in annual report for 2021

Feb. 21, 2023
By Mark McCarty
No Comments
The U.S. Federal Trade Commission (FTC) released its annual premerger notification report, this one for fiscal year 2021, during which more than 3,400 transactions were reported under the Hart-Scott-Rodino Act (HRS Act). Roughly 17% of these were valued at more than $1 billion, but the FTC is facing bad publicity with the resignation of the sole Republican member of the commission, Christine Wilson, who charged FTC chairwoman Lina Khan with abuse of power.
Read More

Biogen terminates collaboration with Innocare on orelabrutinib

Feb. 21, 2023
By Doris Yu
No Comments
Innocare Pharma Ltd. said it is open to new collaborations after partner Biogen Inc. decided to terminate a global deal to develop and commercialize BTK inhibitor orelabrutinib, in development for multiple sclerosis and other autoimmune diseases. Notice of the termination, disclosed in Biogen’s fourth-quarter 2022 financial report, was “based on the contract term of ‘terminate for convenience,’” Innocare told BioWorld. “We do not know their internal decision-making process.”
Read More
Previous 1 2 3 4 5 6 7 8 9 … 173 174 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 29, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for March 29, 2023.
  • Kirill Pevzner and Eran Seger - Protai

    AI drug discovery startup Protai raises $12M in seed funding

    BioWorld
    Artificial intelligence (AI)-powered drug discovery startup Protai Bio Ltd. raised $12 million in additional seed funding, bringing the total amount to $20...
  • Elderly woman holding illustration of brain with missing puzzle piece

    ‘Not a slowdown, a reversal’: Truebinding tackling Alzheimer’s via galectin-3

    BioWorld
    In Alzheimer’s, the amyloid beta hypothesis has proved most persistent in terms of drug development efforts to date, but aggregation of other pathogenic factors –...
  • DNA in drug capsules

    Oh drat, OTAT: FDA’s turnaround on adcom for DMD prospect clips Sarepta shares

    BioWorld
    Sarepta Therapeutics Inc. CEO Doug Ingram said the U.S. FDA has promised to schedule “expeditiously” an advisory committee meeting on the BLA related to SRP-9001...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing